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Abstract 
Glioblastoma (GBM) is the most common and malignant primary brain tumour with a median 
survival ranging between 12-18 months following standard therapy protocols. Local 
recurrence post-resection and adjuvant treatment occurs in most cases. Preclinical models 
exist which recapitulate the essential features of GBM. However, few have attempted to 
recapitulate the surgical resection environment and post-resection recurrence. Within the 
current context we have developed a robust methodology for establishing an imageable 
GBM surgical resection animal model. 
Methods: 106 U87-MG luciferase expressing GBM cells were implanted into the right 
hemisphere of  6 week old female rats at predefined stereotactic co-ordinates (n=10). When   
tumour were in exponential growth phase (as measured from tumour emitting 
bioluminescence), animals were randomized into surgical and non-surgical groups. 
Following parenterally delivered anesthesia, animals were fixed in a stereotactic frame. A 
4.5mm craniectomy was performed with resection of the tumour using microsurgical 
techniques. Hemostasis was ensured. The cranial defect was repaired using a novel 
modified cranial window technique consisting of a circular microscope coverslip held in place 
with glue.  
 
Results: 
Immediate post-operative bioluminescence imaging revealed a gross total resection rate of 
75%. At censor point 4 weeks post-resection, Kaplan-Myer survival analysis revealed 100% 
survival in the surgical group compared to 0% in the non-surgical cohort (p=0.01). There 
were no neurological defects or infections in the surgical group. GBM recurrence was 
reliably imageable with a recurrence rate was observed by 4 weeks. 
 
Conclusion: 
We have established a reproducible, imageable surgical resection model of intracranial GBM 
that mimics patient recurrence post-resection.  
 
 
 
Introduction 
 
Glioblastoma (GBM) is the most frequent and malignant primary brain tumour which ac-
counts for approximately 12-15% of all intracranial neoplasms 3. GBM is heterogeneous on a 
genetic, cellular and macroscopic level. Intratumoural hypoxic gradients can drive stem cell 
distribution and effect epigenetic modifications such as MGMT expression. Current standard 
of care for GBM involves surgical resection followed by adjuvant chemo-radiotherapy. Extent 
of surgical resection can have the single greatest survival benefit for patients, with subtotal 
resections up to 78% providing a significant survival advantage 15. It has also been demon-
strated that surgery can improve the efficacy of adjuvant therapy 20.  Despite maximal treat-
ment, GBM is characterized by tumour recurrence and resistance. Recurrence is due to tu-
mour cell migration from the tumour bulk into normal surrounding brain parenchyma to 
where it is protected by an intact blood-brain-barrier.  Resistance is due to complex intracel-
lular and extracellular mechanisms. Genetic and epigenetic factors, tumour cell heterogenei-
ty including the presence of stem cells, as well as the tumour microenvironment have all 
been implicated in resistance to treatment. The survival benefit conferred by surgery may 
derive from the concept of cytoreduction; by removing the bulk of the tumour and therefore 
its constituents implicated in resistance and recurrence, thereby improving the efficacy of 
adjuvant treatment 7,11,12,16,20,23. Surgery also reduces the compressive biomechanical forces 
of the tumour which can influence invasion and proliferation of GBM cells and pharmacody-
namics of the drugs used2,5,17-19,24.  
 Within the pre-clinical setting a majority of studies which employ GBM rodent models in-
volve a non-surgical therapeutic regimen, and do not consider the therapeutic advantage of 
surgery which may significantly reduce the translational context. Herein, we describe the de-
velopment of a novel cost effective imageable rat intracranial GBM surgical resection model. 
We describe a detailed protocol based on a novel modified cranial window technique to sim-
ultaneously repair the craniectomy and permit serial bioluminescence (BLI) imaging over a 
prolonged follow-up period. 
 
Materials and Methods 
Cell culture  
 
U-87 MG-luc2 cells were sub-cultured in a T-75 flask. When the monolayer reached 
approximately 80 % confluence, the waste media was removed and the cells were washed 
with sterile Hanks Balanced Salt Solution (HBSS) (Sigma-Aldrich, St. Louis, MO, USA). Cells 
were then enzymatically detached from the surface of the tissue culture vessel following 
addition of 2 mls of a 0.25 % Trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO, USA). 
The flasks were returned into the incubator for 2-3 minutes and then struck once to ensure 
total cell detachment. The enzyme was inactivated by adding 5ml of volume of complete 
growth medium. The cell suspension was then transferred to a sterile centrifuge tube and 
spun at 1000 rpm for 3 min. The supernatant was removed and the resulting pellet was re-
suspended in 10 ml of culture medium pre-warmed to 37°C and seeded at the 2.1 × 106 
density in a T-75 culture flask. Cells were returned to the incubator and maintained at 37°C 
in humidified air with 5 % CO2. 
Implantation of U87 MG- Luc 2 cells 
 
10 Foxn1rnu T-cell-deficient, athymic nude rats (Charles River Laboratories, Germany) were  
selected as they are suitable for glioblastoma tumour xenograft research 14. The rats were 
weighed and anaesthetized via intraperitoneal delivery of anesthetic (ketamine (80mg/kg)/ 
xylazine 10mg/kg). Respiration was closely monitored along with the general condition of the 
animal. Skin was prepared by removing hair with a depilatory cream. The rats were then 
fixed in a stereotactic frame and the skin was disinfected with alcohol.  
A small right parasagittal skin incision was made followed by a craniostomy with a high 
speed dental drill at the level of the bregma 3mm right of the midline. After the dura was 
punctured, 2µl of cell suspension containing 105 U87 MG-luc 2 cells were aspirated using a 
Hamilton syringe. The syringe was loaded into the stereotactic arm and cell suspension 
slowly injected at a depth of 2.5mm. The syringe was slowly withdrawn. Any residual cell 
suspension removed. The skin was closed in a single layer with 4/0 interrupted simple 
sutures. Animals were monitored post-operatively and returned to their cages when fully 
recovered. All animal experiments were licensed by the Department of Health and Children, 
Dublin, Ireland. Protocols were reviewed by the Royal College of Surgeons in Ireland (RCSI) 
Animal Research Ethics Committee (AREC).  
Bioluminescence imaging (BLI)  
 
D-Luciferin [d-(-)-2-(60-hydroxy-20-benzothiazolyl)-thiazone-4-carboxylic acid] (Caliper Life 
Sciences, USA) was formulated in a 30mg/ml solution of DPBS without calcium and 
magnesium, filtered through a 0.22 µm filter, and protected from light. A kinetic study was 
performed at week 1 and 2 post implantation to generate a kinetic curve of luciferase activity.  
Images were analyzed with Living Image® Software (PerkinElmer Inc.) using fixed regions of 
interest. Animals were imaged in identical fashion each week using peak signal time 
established by the week 2 kinetic study. 
 
Surgical resection 
 
When tumors were in exponential growth phase as determined by bioluminescence signal, 
the animals were randomized into 2 groups: Control/Non-surgical group and surgical group. 
Rats were weighed and intraperitoneal delivery of anesthetic [ketamine (80mg/kg)/ xylazine 
10mg/kg]. No antibiotics were administered for the experiment. Animal respiration and 
general condition were closely monitored. The skin was prepared by removing hair with a 
depilatory cream. The rats were then fixed in a stereotactic frame and the skin was prepared 
in standard surgical fashion.  
Previous skin incision was extended in a curvilinear fashion and tissues reflected back. The 
temporalis muscle was sharply dissected from the cranium and reflected and the 
pericranium incised and also reflected. The previous burr hole was identified. Using an 
operating microscope and high-speed dental drill a 4.5mm craniectomy was made centered 
on the previous burr hole. A durotomy was made and the tumour located. The tumour was 
gently dissected free (see figure 1). Hemostasis was achieved with a hand-held 
electrocautery pen with a fine needle tip. The surgical cavity was irrigated and filled with 
sterile saline. 
To repair the cranial defect and to permit post-operative BLI, 5mm sterile circular glass 
microscope coverslips were placed and fixed with cyanoacrylate glue (see figure 1). The skin 
was closed in a single layer over the cranial window with 4/0 interrupted simple sutures and 
cleaned with alcohol (see figure 1). Animals underwent immediate post-operative BLI and 
were returned to their cage when fully recovered (see figure 2). Animals were weighed daily 
and assessed for wound infection and general condition. Neurological function was 
assessed by a previously described method using a modified rat coma scale1. 
Statistical Analysis 
Kaplan-Meier survival analysis and graphs were collated using GraphPad Prism 5 ®.   
 
Results 
 
Bioluminescence signal as a marker of pre-operative tumour  growth 
We performed bioluminescence imaging of animals at weekly intervals to assess tumour 
growth. Total photon flux was plotted each week. From this we established that all tumors 
were in the exponential growth phase by week 4.5. (see figure 3).  At this time point the 
animals were randomized into surgical and non-surgical/control groups.  
Bioluminescence signal to establish extent of resection and tumour 
recurrence. 
Those animals undergoing surgical resection had bioluminescence imaging immediately pre-
operatively and post-operatively (see figure 3). From this we established that we had 
achieved a gross total resection rate of 75%. In one single rat we were able to detect tumour 
signal quantified at 7.58x104 photons/sec/cm2. Although this was below background 
threshold levels, we consider this to be a sub-total resection as it was two-times the total flux 
of the other surgical resection animals (mean 3.06x104 photons/sec/cm2. Post-operative 
bioluminescence imaging analysis reveals that we achieved greater than 99% reduction in 
total photon flux.  
Each post-operative week the animals were imaged in identical fashion and the total photon 
flux plotted. There was a stepwise incidence of tumour recurrence as noted by 
bioluminescence signal beginning with the rat that had the sub-total resection. By the fourth 
post-operative week the mean signal of the operative group exceeded the pre-operative 
mean total photon flux ( 1.83x108  v 2.61x108 photons/sec/cm2 ) (see figure 4 & 5).  
Surgical resection of the intracranial tumour increases survival. 
 
All surgical animals survived to the end of the study period. Censor point was at 4 weeks to 
facilitate further histological analyses. In the surgical group, weights and general condition 
were consistent throughout the study period. Kaplan-Meier Survival analysis revealed 
surgery conferred a statistically significant survival advantage (Log-Rank p=0.01) (see figure 
6) 
Histology 
 
Post mortem histological analysis revealed a marked unilateral tumour causing mass effect 
in the superficial cortex of the non-surgical/control animals. These tumors display patchy 
areas of necrosis surrounded by areas of pseudopallisading. There was marked 
neovascularization with minimal invasion into the surrounding normal brain parenchyma (see 
figure 7 & 8). In animals that underwent surgery, the resection cavity was apparent and both 
histological examination and ex-vivo BLI signal confirmed tumour in this cavity. (see figure 9). 
Discussion 
 
To date a limited number of studies have utilized any form of intracranial surgical resection in 
pre-clinical GBM models 1,4,25. These studies have relied only on survival analysis and histol-
ogy to interpret the efficacy of intracavity chemotherapeutics. Moreover, such resection 
models ostensibly lack any attempt to longitudinally assess treatment response via molecu-
lar imaging. Thus, to extend and improve upon efforts to date we have developed a novel rat 
based xenograft model wherein bioluminescence imaging combined with a modified cranial 
window technique facilitates serial imaging follow-up.  
To our knowledge, just two studies have utilized a BLI surgical resection model of GBM. The 
first investigated encapsulated stem cell migration in combination with intravital microscopy 
8.  In this paper the authors successfully used a “cranial window” to perform surgical resec-
tion and deliver encapsulated stem cells. The “cranial window” as described consisted of 
craniectomy only, with direct wound closure. In the second surgical resection paper that em-
ployed BLI, the authors also did not repair the cranial defect6. The limitation of this approach 
is that the surgical resection cavity is in direct continuation with the subgaleal space which 
may preclude this model from being used in the development of intracavity delivery of novel 
non-biological agents, particularly cytotoxic agents. Within the clinical context (based on the 
author’s observations) use of carmustine wafers elicits a higher incidence of wound compli-
cations when the dura is not closed in a watertight fashion.  Thus, herein we have described 
a detailed step-by-step procedure for performing intracranial surgical resection and cranial 
defect repair, which separates the surgical cavity from the overlying tissues and enables fac-
ile non-invasive bioluminescence imaging follow-up.  
Hallmarks of the natural history of GBM, despite maximal standard therapy are recurrence 
and resistance, or poor response to re-treatment and second line/salvage therapy. It is clear 
that extent of tumour resection is an important determinant of survival and it has been sug-
gested that it may also improve the efficacy of adjuvant treatment 20,21. In the current context 
we have successfully recapitulated the clinical GBM resection strategy. Our data closely cor-
relates with observations from clinical practice. We achieved a gross total resection rate of 
75% with a 75% recurrence rate at four weeks. Clinically, depending on the neurosurgical 
centre and the methods employed to maximize surgical resection, gross total resection rates 
have been reported in the  65%-94% range 9,10,22. We have also demonstrated a survival 
benefit due to surgery alone as noted by a week 4 censored Kaplan-Meier analysis (p=0.01). 
This also reflects clinically observed survival benefits. Previous studies have shown that pa-
tients who undergo biopsy only, have poorer survival rates than those who have had a surgi-
cal resection 13.  
Perhaps the most important finding in our current study is the ability to image tumour recur-
rence post-surgical resection. Application of a surgical resection rat model (as distinct from 
mouse) in pre-clinical GBM therapeutic efficacy studies may better facilitate: (1) the study of 
combinatorial and sub-chronic/chronic dosing regimens due to practical benefits associated 
with larger rodents (e.g. ability to more easily perform repeated oral/ intravenous dosing pro-
cedure), (2) may facilitate improved application of state of the art translational molecular im-
aging strategies with specific application in the study of GBM (e.g. CT and functional MRI),  
and (3) may also better integrate with rodent toxicology (rat) studies generally required for 
regulatory approval of novel targeted therapies/ combinatorial treatment strategies. 
Conclusion 
 
We have established an imageable surgical resection rat model of GBM. This model will ac-
count for the therapeutic benefit of surgical resection in pre-clinical models.This model may 
also account for one of the main reasons of treatment failure, residual tumour protected by 
an intact BBB.  
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Figure 1-Detailed step-by-step description of surgical resection procedure. (i) 4.5 mm 
Craniectomy is fashioned with a high speed drill. Note the tumour presents itself into the 
craniectomy defect. (ii) Once the tumour is resected the surgical resection cavity is available 
to receive intracavity delivery of therapeutic agents. (iii) The modified cranial window 
technique that facilities the repair of the cranial defect allowing separation of the surgical 
resection cavity from the overlying tissues and simultaneously allowing bioluminescence 
imaging. The cranial window consists of a circular microscope coverslip help in situ with 
cyanoacrylate glue. Magnification 1x (iv) Closer view of the modified cranial window at a 
magnification of 3x demonstrating an air fluid level within the contained surgical resection 
cavity. (iv) After the cranial defect is repaired the wound is closed with simple interrupted 
absorbable sutures.  
 Figure 2- The Immediate post-operative Bioluminescence (BLI) imaging of the four animals 
that underwent surgical resection to establish the extent of resection. Note in all four animals 
(i)-(iv) there is a sharp reduction in the BLI signal. In (ii) the BLI signal over the surgical 
resection cavity was twice that of the others but remained below acceptable levels. 
 Figure 3- Longitudinal Bioluminescence (BLI) imaging of tumour growth after implantation 
and before surgical resection demonstrating the growth curve of the tumors before the 
animals were randomized into surgical and non-surgical groups. Whiskers represent SEM. 
  
Figure 4- Longitudinal Bioluminescence (BLI) imaging of tumour growth of surgical group 
(grey) and non-surgical (black) groups. The sharp drop in the surgical group represents the 
time of surgical resection. Note the ability to longitudinally follow tumour recurrence in vivo 
after the cranial defect is repaired. Whiskers represent SEM. 
 
 Figure 5- Representative longitudinal Bioluminescence (BLI) images from (i) surgical and (ii) 
non-surgical groups with corresponding ex-vivo images. Note in the surgical group the 
obvious drop in BLI in immediate post-operative image and the facile method of 
longitudinally imaging tumor recurrence. 
 
 
Figure 6- Kaplan-Meier survival curves of the surgical and non-surgical groups. Surgical 
resection of the tumors conferred a significant survival benefit group when compared to the 
control group. P<0.05. 
 
 
Figure 7- Low magnification micrograph in the coronal plane of non-surgical group using 
H&E staining demonstrating a dense cellular Glioblastoma U87-MG tumour in the subcortical 
area indicated by the white arrow. Magnification 20x 
 
 
Figure 8- Higher magnification micrograph image of figure 35. Magnification 40x. White 
arrow indicates the dense cellular subcortical GBM. 
 
Figure 9- Low magnification micrograph image of the surgical resection cavity demonstrating 
residual tumour that has infiltrated the surgical resection cavity leading to tumour recurrence 
which, using this model, we are able to image longitudinally in vivo. Residual tumor is 
indicated with arrows.   H&E staining. Magnification 4x. 
 
